{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T22:00:29Z","timestamp":1790632829715,"version":"4.1.0"},"reference-count":96,"publisher":"Frontiers Media SA","funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["MOP-86514"],"award-info":[{"award-number":["MOP-86514"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"DOI":"10.3389\/fphar.2016.00160","type":"journal-article","created":{"date-parts":[[2016,6,22]],"date-time":"2016-06-22T03:24:36Z","timestamp":1466565876000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":100,"title":["Pharmacological Targeting of the Hepcidin\/Ferroportin Axis"],"prefix":"10.3389","volume":"7","author":[{"given":"Giada","family":"Sebastiani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Wilkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kostas","family":"Pantopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2016,6,21]]},"reference":[{"key":"B1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V118.21.688.688","article-title":"Targeting the hepcidin pathway with RNAi therapeutics for the treatment of Anemia","volume-title":"53th Annual Meeting of the American Society for Hematology (ASH)","author":"Akinc","year":"2011"},{"key":"B2","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.chom.2014.12.001","article-title":"Hepcidin-induced hypoferremia is a critical host defense mechanism against the siderophilic bacterium Vibrio vulnificus","volume":"17","author":"Arezes","year":"2015","journal-title":"Cell Host Microbe"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e1608","DOI":"10.1542\/peds.2010-1123","article-title":"Iron-deficiency anemia in Castleman disease: implication of the interleukin 6\/hepcidin pathway","volume":"126","author":"Arlet","year":"2010","journal-title":"Pediatrics"},{"issue":"316","key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2015.00316","article-title":"High sulfation and a high molecular weight are important for anti-hepcidin activity of heparin","volume":"6","author":"Asperti","year":"2016","journal-title":"Front. Pharmacol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/ng1777","article-title":"Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression","volume":"38","author":"Babitt","year":"2006","journal-title":"Nat. Genet."},{"key":"B6","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1681\/ASN.2013040355","article-title":"Suppression of iron-regulatory hepcidin by vitamin D","volume":"25","author":"Bacchetta","year":"2014","journal-title":"J. Am. Soc. Nephrol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1586\/17474086.2016.1124757","article-title":"Modulation of hepcidin to treat iron deregulation: potential clinical applications","volume":"9","author":"Blanchette","year":"2016","journal-title":"Expert Rev. Hematol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1016\/j.biocel.2010.07.018","article-title":"Dorsomorphin and LDN-193189 inhibit BMP-mediated Smad, p38 and Akt signalling in C2C12 cells","volume":"42","author":"Boergermann","year":"2010","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1208\/s12248-015-9770-4","article-title":"Anti-repulsive guidance molecule C (RGMc) antibodies increases serum iron in rats and cynomolgus monkeys by hepcidin downregulation","volume":"17","author":"B\u00f6ser","year":"2015","journal-title":"AAPS J."},{"key":"B10","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1111\/bjh.13820","article-title":"Ineffective erythropoiesis and regulation of iron status in iron loading anaemias","volume":"172","author":"Camaschella","year":"2016","journal-title":"Br. J. Haematol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"4294","DOI":"10.1158\/1078-0432.CCR-15-0134","article-title":"Analysis of inflammatory and anemia-related biomarkers in a randomized, double-blind, placebo-controlled study of siltuximab (Anti-IL6 Monoclonal Antibody) in patients with multicentric castleman disease","volume":"21","author":"Casper","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-10-676742","article-title":"Minihepcidin peptides as disease modifiers in mice affected by beta-thalassemia and polycythemia vera","author":"Casu","year":"2016","journal-title":"Blood."},{"key":"B13","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/nrd4503","article-title":"A holistic approach to targeting disease with polymeric nanoparticles","volume":"14","author":"Cheng","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"B14","doi-asserted-by":"publisher","first-page":"4961","DOI":"10.1016\/j.bmcl.2015.03.012","article-title":"Small cyclic agonists of iron regulatory hormone hepcidin","volume":"25","author":"Chua","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"B15","doi-asserted-by":"publisher","first-page":"3054","DOI":"10.1182\/blood-2013-06-505792","article-title":"A fully human anti-hepcidin antibody modulates iron metabolism in both mice and nonhuman primates","volume":"122","author":"Cooke","year":"2013","journal-title":"Blood"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1053\/j.gastro.2010.07.044","article-title":"BMP6 treatment compensates for the molecular defect and ameliorates hemochromatosis in Hfe knockout mice","volume":"139","author":"Corradini","year":"2010","journal-title":"Gastroenterology"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1093\/rheumatology\/kes381","article-title":"Effects of subcutaneous and intravenous golimumab on inflammatory biomarkers in patients with rheumatoid arthritis: results of a phase 1, randomized, open-label trial","volume":"52","author":"Doyle","year":"2013","journal-title":"Rheumatology"},{"key":"B18","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.cmet.2015.09.006","article-title":"Ironing out Ferroportin","volume":"22","author":"Drakesmith","year":"2015","journal-title":"Cell Metab."},{"key":"B19","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s00109-009-0588-3","article-title":"Natural and synthetic STAT3 inhibitors reduce hepcidin expression in differentiated mouse hepatocytes expressing the active phosphorylated STAT3 form","volume":"88","author":"Fatih","year":"2010","journal-title":"J. Mol. Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"4590","DOI":"10.1182\/blood-2010-10-315507","article-title":"Tmprss6 is a genetic modifier of the Hfe-hemochromatosis phenotype in mice","volume":"117","author":"Finberg","year":"2011","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.1056\/NEJMc1010939","article-title":"Investigation of a researcher's death due to septicemic plague","volume":"364","author":"Frank","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1124\/mol.112.083428","article-title":"High-throughput screening of small molecules identifies hepcidin antagonists","volume":"83","author":"Fung","year":"2013","journal-title":"Mol. Pharmacol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1152\/physrev.00008.2013","article-title":"Systemic iron homeostasis","volume":"93","author":"Ganz","year":"2013","journal-title":"Physiol. Rev."},{"key":"B24","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/nri3863","article-title":"Iron homeostasis in host defence and inflammation","volume":"15","author":"Ganz","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"4466","DOI":"10.1172\/JCI41717","article-title":"Hepcidin as a therapeutic tool to limit iron overload and improve anemia in beta-thalassemic mice","volume":"120","author":"Gardenghi","year":"2010","journal-title":"J. Clin. Invest."},{"key":"B26","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.bcmd.2014.06.002","article-title":"A chemical screen identifies small molecules that regulate hepcidin expression","volume":"53","author":"Gaun","year":"2014","journal-title":"Blood Cells Mol. Dis."},{"key":"B27","doi-asserted-by":"publisher","first-page":"4321","DOI":"10.1182\/blood-2011-03-283614","article-title":"beta-thalassemia: a model for elucidating the dynamic regulation of ineffective erythropoiesis and iron metabolism","volume":"118","author":"Ginzburg","year":"2011","journal-title":"Blood"},{"key":"B28","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.bbagen.2011.10.013","article-title":"Regulation of iron transport and the role of transferrin","volume":"1820","author":"Gkouvatsos","year":"2012","journal-title":"Biochim. Biophys. Acta"},{"key":"B29","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1182\/blood-2014-08-595256","article-title":"A novel inflammatory pathway mediating rapid hepcidin-independent hypoferremia","volume":"125","author":"Guida","year":"2015","journal-title":"Blood"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1172\/JCI66969","article-title":"Reducing TMPRSS6 ameliorates hemochromatosis and beta-thalassemia in mice","volume":"123","author":"Guo","year":"2013a","journal-title":"J. Clin. Invest."},{"key":"B31","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1111\/acel.12052","article-title":"Testosterone administration inhibits hepcidin transcription and is associated with increased iron incorporation into red blood cells","volume":"12","author":"Guo","year":"2013b","journal-title":"Aging Cell"},{"key":"B32","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1007\/s00296-009-1075-4","article-title":"Tocilizumab, a humanized anti-interleukin-6 receptor antibody, improved anemia in monkey arthritis by suppressing IL-6-induced hepcidin production","volume":"30","author":"Hashizume","year":"2010","journal-title":"Rheumatol. Int."},{"key":"B33","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.hoc.2014.04.009","article-title":"Iron-Refractory Iron Deficiency Anemia (IRIDA)","volume":"28","author":"Heeney","year":"2014","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"B34","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V118.21.687.687","article-title":"Discovery and preclinical characterization of a novel hepcidin antagonist with tunable PK\/PD properties for the treatment of anemia in different patient populations","volume-title":"53th Annual Meeting of the American Society for Hematology (ASH)","author":"Hohlbaum","year":"2011"},{"key":"B35","doi-asserted-by":"publisher","first-page":"R204","DOI":"10.1186\/ar4397","article-title":"Effect of tocilizumab on haematological markers implicates interleukin-6 signalling in the anaemia of rheumatoid arthritis","volume":"15","author":"Isaacs","year":"2013","journal-title":"Arthritis Res. Ther."},{"key":"B36","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1182\/blood-2008-05-155952","article-title":"Curcumin, a cancer chemopreventive and chemotherapeutic agent, is a biologically active iron chelator","volume":"113","author":"Jiao","year":"2009","journal-title":"Blood"},{"key":"B37","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1097\/MOH.0000000000000132","article-title":"New insights into iron regulation and erythropoiesis","volume":"22","author":"Kim","year":"2015","journal-title":"Curr. Opin. Hematol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"e173","DOI":"10.3324\/haematol.2015.140772","article-title":"Anti-hemojuvelin antibody corrects anemia caused by inappropriately high hepcidin levels","volume":"101","author":"Kovac","year":"2016","journal-title":"Haematologica"},{"key":"B39","doi-asserted-by":"publisher","first-page":"3164","DOI":"10.1073\/pnas.1422373112","article-title":"Cardiac ferroportin regulates cellular iron homeostasis and is important for cardiac function","volume":"112","author":"Lakhal-Littleton","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B40","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1002\/hep.26648","article-title":"Testosterone perturbs systemic iron balance through activation of epidermal growth factor receptor signaling in the liver and repression of hepcidin","volume":"59","author":"Latour","year":"2014","journal-title":"Hepatology"},{"key":"B41","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1172\/JCI83831","article-title":"Progesterone receptor membrane component-1 regulates hepcidin biosynthesis","volume":"126","author":"Li","year":"2016","journal-title":"J. Clin. Invest."},{"key":"B42","doi-asserted-by":"publisher","first-page":"2884","DOI":"10.1182\/blood-2005-05-1845","article-title":"Competitive regulation of hepcidin mRNA by soluble and cell-associated hemojuvelin","volume":"106","author":"Lin","year":"2005","journal-title":"Blood"},{"key":"B43","doi-asserted-by":"publisher","first-page":"e3150","DOI":"10.1097\/MD.0000000000003150","article-title":"Hepcidin: a promising therapeutic target for iron disorders: a systematic review","volume":"95","author":"Liu","year":"2016","journal-title":"Medicine"},{"key":"B44","doi-asserted-by":"publisher","first-page":"4148","DOI":"10.1182\/blood-2002-08-2459","article-title":"Cytokine-mediated regulation of iron transport in human monocytic cells","volume":"101","author":"Ludwiczek","year":"2003","journal-title":"Blood"},{"key":"B45","doi-asserted-by":"publisher","first-page":"e68","DOI":"10.3324\/haematol.2014.111484","article-title":"Oral administration of a bone morphogenetic protein type I receptor inhibitor prevents the development of anemia of inflammation","volume":"100","author":"Mayeur","year":"2015","journal-title":"Haematologica"},{"key":"B46","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.jhep.2010.05.016","article-title":"Ferroportin disease: a systematic meta-analysis of clinical and molecular findings","volume":"53","author":"Mayr","year":"2010","journal-title":"J. Hepatol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"2663","DOI":"10.1210\/en.2006-1331","article-title":"The iron regulatory peptide hepcidin is expressed in the heart and regulated by hypoxia and inflammation","volume":"148","author":"Merle","year":"2007","journal-title":"Endocrinology"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1182\/blood-2013-07-515957","article-title":"Unbiased RNAi screen for hepcidin regulators links hepcidin suppression to proliferative Ras\/RAF and nutrient-dependent mTOR signaling","volume":"123","author":"Mleczko-Sanecka","year":"2014","journal-title":"Blood"},{"key":"B49","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.536.536","article-title":"A phase I study investigating the safety, tolerability, pharmacokinetics and pharmacodynamic activity of the hepcidin antagonist PRS-080#022. Results from a randomized, placebo controlled, double-blind study following single administration to healthy subjects","volume-title":"57th Annual Meeting of the American Society for Hematology (ASH)","author":"Moebius","year":"2015"},{"key":"B50","doi-asserted-by":"publisher","first-page":"5021","DOI":"10.1182\/blood-2012-01-401885","article-title":"Deletion of TMPRSS6 attenuates the phenotype in a mouse model of beta-thalassemia","volume":"119","author":"Nai","year":"2012","journal-title":"Blood"},{"key":"B51","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1182\/blood-2015-11-681494","article-title":"Limiting hepatic Bmp-Smad signaling by matriptase-2 is required for erythropoietin-mediated hepcidin suppression in mice","volume":"127","author":"Nai","year":"2016","journal-title":"Blood"},{"key":"B52","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/ng1150","article-title":"Constitutive hepcidin expression prevents iron overload in a mouse model of hemochromatosis","volume":"34","author":"Nicolas","year":"2003","journal-title":"Nat. Genet."},{"key":"B53","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.taap.2004.06.021","article-title":"Iron metabolism and toxicity","volume":"202","author":"Papanikolaou","year":"2005","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"2800","DOI":"10.1182\/blood-2010-09-309708","article-title":"Prevalence of 25-hydroxyvitamin D deficiency in subgroups of elderly persons with anemia: association with anemia of inflammation","volume":"117","author":"Perlstein","year":"2011","journal-title":"Blood"},{"key":"B55","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.273.273","article-title":"ALK2 Inhibition via TP-0184 abrogates inflammation-induced hepcidin expression and is a potential therapeutic for anemia of chronic disease","volume-title":"57th Annual Meeting of the American Society for Hematology (ASH)","author":"Peterson","year":"2015"},{"key":"B56","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1053\/j.gastro.2015.06.045","article-title":"Genetics, genetic testing, and management of hemochromatosis: 15 years since hepcidin","author":"Pietrangelo","year":"2015","journal-title":"Gastroenterology 149"},{"key":"B57","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/liv.13020","article-title":"Iron and the liver","volume":"36","author":"Pietrangelo","year":"2016","journal-title":"Liver Int."},{"key":"B58","doi-asserted-by":"publisher","first-page":"43ra56","DOI":"10.1126\/scitranslmed.3001127","article-title":"Ferroportin and iron regulation in breast cancer progression and prognosis","volume":"2","author":"Pinnix","year":"2010","journal-title":"Sci. Transl. Med."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1182\/blood-2013-07-515221","article-title":"Glycol-split nonanticoagulant heparins are inhibitors of hepcidin expression in vitro and in vivo","volume":"123","author":"Poli","year":"2014a","journal-title":"Blood"},{"key":"B60","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.bcp.2014.09.007","article-title":"Oversulfated heparins with low anticoagulant activity are strong and fast inhibitors of hepcidin expression in vitro and in vivo","volume":"92","author":"Poli","year":"2014b","journal-title":"Biochem. Pharmacol."},{"issue":"86","key":"B61","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2014.00086","article-title":"Hepcidin antagonists for potential treatments of disorders with hepcidin excess","volume":"5","author":"Poli","year":"2014c","journal-title":"Front. Pharmacol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1182\/blood-2010-06-289082","article-title":"Heparin: a potent inhibitor of hepcidin expression in vitro and in vivo","volume":"117","author":"Poli","year":"2011","journal-title":"Blood"},{"key":"B63","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/nm.2368","article-title":"Host-mediated regulation of superinfection in malaria","volume":"17","author":"Portugal","year":"2011","journal-title":"Nat. Med."},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01315-X","article-title":"Haemochromatosis","author":"Powell","year":"2016","journal-title":"Lancet"},{"key":"B65","doi-asserted-by":"publisher","first-page":"4880","DOI":"10.1172\/JCI57693","article-title":"Minihepcidins are rationally designed small peptides that mimic hepcidin activity in mice and may be useful for the treatment of iron overload","volume":"121","author":"Preza","year":"2011","journal-title":"J. Clin. Invest."},{"key":"B66","doi-asserted-by":"publisher","first-page":"3829","DOI":"10.1182\/blood-2012-07-440743","article-title":"Minihepcidins prevent iron overload in a hepcidin-deficient mouse model of severe hemochromatosis","volume":"120","author":"Ramos","year":"2012","journal-title":"Blood"},{"key":"B67","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.pharmthera.2014.09.004","article-title":"The iron-regulatory hormone hepcidin: a possible therapeutic target?","volume":"146","author":"Rochette","year":"2015","journal-title":"Pharmacol. Ther."},{"key":"B68","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.tips.2014.01.004","article-title":"The pathophysiology and pharmacology of hepcidin","volume":"35","author":"Ruchala","year":"2014","journal-title":"Trends Pharmacol. Sci."},{"key":"B69","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1161\/ATVBAHA.111.240101","article-title":"Pharmacological suppression of hepcidin increases macrophage cholesterol efflux and reduces foam cell formation and atherosclerosis","volume":"32","author":"Saeed","year":"2012","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"3616","DOI":"10.1182\/blood-2009-09-245977","article-title":"Antihepcidin antibody treatment modulates iron metabolism and is effective in a mouse model of inflammation-induced anemia","volume":"115","author":"Sasu","year":"2010","journal-title":"Blood"},{"key":"B71","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.hoc.2013.11.004","article-title":"Modulation of hepcidin as therapy for primary and secondary iron overload disorders: preclinical models and approaches","volume":"28","author":"Schmidt","year":"2014","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"B72","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood-2012-09-453977","article-title":"An RNAi therapeutic targeting Tmprss6 decreases iron overload in Hfe(-\/-) mice and ameliorates anemia and iron overload in murine beta-thalassemia intermedia","volume":"121","author":"Schmidt","year":"2013","journal-title":"Blood"},{"key":"B73","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1182\/blood-2012-09-456756","article-title":"The effects of the anti-hepcidin Spiegelmer NOX-H94 on inflammation-induced anemia in cynomolgus monkeys","volume":"121","author":"Schwoebel","year":"2013","journal-title":"Blood"},{"key":"B74","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1039\/c1mt00082a","article-title":"Disorders associated with systemic or local iron overload: from pathophysiology to clinical practice","volume":"3","author":"Sebastiani","year":"2011","journal-title":"Metallomics"},{"key":"B75","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1016\/j.jhep.2013.05.045","article-title":"Liver as a target for oligonucleotide therapeutics","volume":"59","author":"Sehgal","year":"2013","journal-title":"J. Hepatol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"395","DOI":"10.4254\/wjh.v8.i8.395","article-title":"Management of human factors engineering-associated hemochromatosis: a 2015 update","volume":"8","author":"Sivakumar","year":"2016","journal-title":"World J. Hepatol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"R141","DOI":"10.1186\/ar4323","article-title":"Comparative evaluation of the effects of treatment with tocilizumab and TNF-alpha inhibitors on serum hepcidin, anemia response and disease activity in rheumatoid arthritis patients","volume":"15","author":"Song","year":"2013","journal-title":"Arthritis Res. Ther."},{"key":"B78","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1182\/blood-2010-03-271791","article-title":"Down-regulation of hepcidin resulting from long-term treatment with an anti-IL-6 receptor antibody (tocilizumab) improves anemia of inflammation in multicentric Castleman disease","volume":"116","author":"Song","year":"2010","journal-title":"Blood"},{"key":"B79","doi-asserted-by":"publisher","first-page":"4915","DOI":"10.1182\/blood-2010-10-313064","article-title":"Inhibition of bone morphogenetic protein signaling attenuates anemia associated with inflammation","volume":"117","author":"Steinbicker","year":"2011","journal-title":"Blood"},{"key":"B80","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1093\/ndt\/gfs584","article-title":"A hepcidin lowering agent mobilizes iron for incorporation into red blood cells in an adenine-induced kidney disease model of anemia in rats","volume":"28","author":"Sun","year":"2013","journal-title":"Nephrol. Dial. Transplant."},{"key":"B81","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1158\/0008-5472.CAN-14-2465","article-title":"Hepcidin regulation in prostate and its disruption in prostate cancer","volume":"75","author":"Tesfay","year":"2015","journal-title":"Cancer Res."},{"key":"B82","doi-asserted-by":"publisher","first-page":"4977","DOI":"10.1182\/blood-2011-03-345066","article-title":"Pharmacologic inhibition of hepcidin expression reverses anemia of chronic inflammation in rats","volume":"118","author":"Theurl","year":"2011","journal-title":"Blood"},{"key":"B83","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/1744-9987.12001","article-title":"Hepcidin is a potential regulator of iron status in chronic kidney disease","volume":"17","author":"Tsuchiya","year":"2013","journal-title":"Ther. Apher. Dial."},{"key":"B84","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1111\/jnc.12244","article-title":"Inflammation alters the expression of DMT1, FPN1 and hepcidin, and it causes iron accumulation in central nervous system cells","volume":"126","author":"Urrutia","year":"2013","journal-title":"J. Neurochem."},{"key":"B85","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.537.537","article-title":"Phase 1 study of a hepcidin antagonist, LY2787106, in cancer-associated anemia","volume-title":"57th Annual Meeting of the American Society for Hematology (ASH)","author":"Vadhan-Raj","year":"2015"},{"key":"B86","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1182\/blood-2014-03-559484","article-title":"Effect of the antihepcidin Spiegelmer lexaptepid on inflammation-induced decrease in serum iron in humans","volume":"124","author":"Van Eijk","year":"2014","journal-title":"Blood"},{"key":"B87","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1097\/MOH.0000000000000236","article-title":"Hepcidin regulation in the anemia of inflammation","volume":"23","author":"Wang","year":"2016","journal-title":"Curr. Opin. Hematol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1053\/j.seminhematol.2015.07.004","article-title":"Anemia of chronic disorders: new diagnostic tools and new treatment strategies","volume":"52","author":"Weiss","year":"2015","journal-title":"Semin. Hematol."},{"key":"B89","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.3433.3433","article-title":"LY2928057, an antibody targeting ferroportin, is a potent inhibitor of hepcidin activity and increases iron mobilization in normal cynomolgus monkeys","volume-title":"55th Annual Meeting of the American Society for Hematology (ASH)","author":"Witcher","year":"2013"},{"key":"B90","doi-asserted-by":"publisher","first-page":"3170","DOI":"10.1210\/en.2011-2045","article-title":"17beta-Estradiol inhibits iron hormone hepcidin through an estrogen responsive element half-site","volume":"153","author":"Yang","year":"2012","journal-title":"Endocrinology"},{"key":"B91","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/nchembio.2007.54","article-title":"Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism","volume":"4","author":"Yu","year":"2008","journal-title":"Nat. Chem. Biol."},{"key":"B92","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1097\/ALN.0000000000000466","article-title":"Hepatic hepcidin protects against polymicrobial sepsis in mice by regulating host iron status","volume":"122","author":"Zeng","year":"2015","journal-title":"Anesthesiology"},{"key":"B93","doi-asserted-by":"publisher","first-page":"5032","DOI":"10.3748\/wjg.v17.i45.5032","article-title":"AG490: an inhibitor of hepcidin expression in vivo","volume":"17","author":"Zhang","year":"2011","journal-title":"World J. Gastroenterol."},{"key":"B94","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1002\/hep.26490","article-title":"The small molecule, genistein, increases hepcidin expression in human hepatocytes","volume":"58","author":"Zhen","year":"2013","journal-title":"Hepatology"},{"key":"B95","doi-asserted-by":"publisher","first-page":"139","DOI":"10.4254\/wjh.v8.i3.139","article-title":"Advances in hepatitis C therapy: what is the current state - what come's next?","volume":"8","author":"Zopf","year":"2016","journal-title":"World J. Hepatol."},{"key":"B96","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.jcte.2014.01.003","article-title":"The role of vitamin D in regulating the iron-hepcidin-ferroportin axis in monocytes","volume":"1","author":"Zughaier","year":"2014","journal-title":"J. Clin. Transl. Endocrinol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"deposited":{"date-parts":[[2020,9,22]],"date-time":"2020-09-22T18:00:46Z","timestamp":1600797646000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/Article\/10.3389\/fphar.2016.00160\/abstract"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,21]]},"references-count":96,"URL":"https:\/\/doi.org\/10.3389\/fphar.2016.00160","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,21]]}}}